logo
  

China Mobile Games And Entertainment Q3 Profit Rises - Quick Facts

China Mobile Games and Entertainment Group Limited (CMGE) said that third-quarter net income attributable to shareholders was RMB75.2 million or US$12.3 million, compared to RMB24.7 million in the comparable quarter last year.

Earnings per American Depositary Share or ADS were RMB2.30 or US$0.38, compared to earnings per ADS of RMB0.98 in the prior year quarter.

Non-GAAP net income was RMB82.8 million or US$13.5 million, compared with non-GAAP net income of RMB24.9 million in the previous year period.

Earnings per ADS excluding share-based compensation and independent committee investigation costs were RMB2.54 or US$0.41, compared with earnings per ADS of RMB0.98 last year.

Total revenues were RMB357.6 million or US$58.3 million, compared with RMB98.1 million in the prior year period. Revenues were 264.5% higher year-over-year. The year-over-year increase was due to the strong growth of self-developed games and publishing business as well, driven by the increase in the number of paying users and ARPU, which, for social games paying users, increased 24.0% and 14.5% quarter-over-quarter, respectively.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT